Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs

International Journal of Pharmaceutics

Volumn 263, Issue 1-2, 2003, Pages 113-122

  Faassen, Fried ^a   Vogel, Gerard ^a   Spanings, Henry ^a   Vromans, Herman ^a,b  

^a NV ORGANON   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Brain penetration; Caco 2; P glycoprotein transport

Indexed keywords

1 (6 CHLORO 5 TRIFLUOROMETHYL 2 PYRIDINYL)PIPERAZINE; 1 [4 [4 (4 TRIFLUOROMETHYL 2 PYRIDINYL) 1 PIPERAZINYL]BUTYL] 2 PYRROLIDINONE 2 BUTENEDIOATE; 1 [4 [4 [BIS(4 FLUOROPHENYL)METHYLENE] 1 PIPERIDINYL] 1 OXOBUTYL]PYRROLIDINE METHANESULFONATE; 2,3,3A,12B TETRAHYDRO 3 METHYL 1H DIBENZO[B,F]OXEPINO[10,11 C]PYRROLE; 3 HYDROXY 4,4 DIMETHYL 1 [4 [4 (2 PYRIMIDINYL) 1 PIPERAZINYL]BUTYL] 2,6 PIPERIDINEDIONE; 4 [(4 FLUOROPHENYL) 4 CHLOROTHIENYL 2 METHYLENE]METHYLPIPERIDINEBUTANE 1,4 DIOATE; 6 (5,6 DIMETHOXYBENZO[B]THIEN 2 YL) 4,5 DIHYDRO 5 METHYL 3(2H) PYRIDAZINONE; ACETYLSALICYLIC ACID; AMITRIPTYLINE; CARBAMAZEPINE; CLONIDINE; DESIPRAMINE; DOMPERIDONE; GEPIRONE; GLYCOPROTEIN P; HALOPERIDOL; HETEROCYCLIC COMPOUND; IBUPROFEN; IMIPRAMINE; INDOMETACIN; MANNITOL; MEPYRAMINE MALEATE; MORPHINE; ORG 12962; ORG 13011; ORG 23366; ORG 23430; ORG 25907; ORG 32782; ORG 34037; ORG 34167; PARACETAMOL; PHENAZONE; QUINIDINE; RANITIDINE; RISPERIDONE; SALICYLIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CELL STRAIN CACO 2; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG PENETRATION; DRUG SCREENING; DRUG TRANSPORT; GASTROINTESTINAL ABSORPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

EID: 0042884316     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00372-7     Document Type: Article

References (47)

1. Adachi Y., Suzuki H., Sugiyama Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm. Res. 18:2001;1660-1668.
2. Ahmed, S., Sproul, C., Hui, A., Hayashi, M., Lau, D.T.W., Young, J.D., Li, J., 2000. Application of Caco-2 model in predicting drug penetration across the blood brain barrier. In: Proceedings of the AAPS Annual Conference, Indianapolis.
3. Baker M.E. Albumin's role in steroid hormone action and the origin of vertebrates: is albumin an essential protein? FEBS Lett. 439:1998;9-12.
4. Baker, J., Osbourn, D., Angus, D., Tasker, E., Stenger, M.A., Martin I., 2002. Effect of pH on the apparent permeability of compounds in the Caco-2 model of intestinal absorption. In: Proceedings of the Annual DMDG meeting, Durham, UK.
5. Boisset M., Botham R.P., Haegele K.D., Lenfant B., Pachot J.I. Absorption of angiotensin II antagonists in Ussing chambers, Caco-2, perfused jejunum loop and in vivo: importance of drug ionisation in the in vitro prediction of in vivo absorption. Eur. J. Pharm. Sci. 10:2000;215-224.
6. Camenisch G., Alsenz J., van de Waterbeemd H., Folkers G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur. J. Pharm. Sci. 6:1998;313-319.
7. Chiou W.L., Chung S.M., Wu T.C., Ma C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther. 39:2001;93-101.
8. Cordon-Cardo C., O'Brien J.P.O., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug resistance gene, (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U.S.A. 86:1989;695-698.
9. Fischer J.M., Wrighton S.A., Calamia J.C., Shen D.D., Kunze K.L. Midazolam metabolism by modified Caco-2 monolayers: effects of extracellular protein binding. J. Pharmacol. Exp. Ther. 289:1999;1143-1150.
10. Fricker G., Drewe J., Huwyler J., Gutmann H., Beglinger C. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br. J. Pharmacol. 118:1996;1841-1847.
11. Gres M.C., Julian B., Bourrie M., Meunier V., Roques C., Berger M., Boulenc X., Berger Y. Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parenteral Caco-2 cell line. Pharm. Res. 15:1998;726-733.
12. Hardman J.G., Limbird, L.E., 1996. Goodman & Gillman's The Pharmacological Basis of Therapeutics. Mc-Graw Hill, New York.
13. a determination of verapamil by liquid-liquid partition. J. Pharm. Sci. 73:1984;442-445.
14. Hendrikse, N.H., 1999. Dynamics of Multidrug Resistance. Analysis with Pet Anad Single Photon Imaging. Ph.D. Thesis. Rijksuniversiteit Groningen, The Netherlands.
15. Karlsson J., Kuo S.M., Ziemniak J., Artursson P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br. J. Pharmacol. 110:1993;1009-1016.
16. Kelder J., Grootenhuis P.D.J., Bayada D.M., Delbressine L.P.C., Ploemen J.P. Polar molecular surface area as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 16:1999;1514-1519.
17. Kragh-Hansen U. Molecular aspects of ligand binding to serum albumin. Pharmacol. Rev. 33:1981;17-53.
18. Lampen A., Bader A., Bestmann T., Winkler M., Witte L., Borlak J.T. Catalytic activities, protein- and mRNA-expression of cytochrome P450 isoenzymes in intestinal cell lines. Xenobiotica. 28:1998;429-441.
19. Lentz K.A., Polli J.W., Wring S.A., Humphreys J.E., Polli J.E. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm. Res. 17:2000;1456-1460.
20. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Del. Rev. 23:1997;3-25.
21. Maher Doan K.M., Humphreys J.E., Webster L.O., Wring S.A., Shampine L.J., Serabjit-Singh C.J., Adkison K.K., Polli J.W. Passive permeability and P-glycoprotein mediated efflux differentiate Central Nervous System (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303:2002;1029-1037.
22. Mizuuchi H., Katsura T., Hashimoto Y., Inui K. Transepithelial transport of diphenhydramine across monolayers of the human intestinal epithelial cell line Caco-2. Pharm. Res. 17:2000;539-545.
23. a values of medicinal compounds in pharmacy practice. Drug Intell. Clin. Pharm. 12:1978;546.
24. Norinder U., Osterberg T., Artursson P. Theoretical calculation and prediction of Caco-2 cell permeability using MolSurf parameterization and PLS statistics. Pharm. Res. 14:1997;1786-1791.
25. Palm K., Stenberg P., Luthman K., Artursson P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14:1997;568-571.
26. Pratt, W.B., Taylor, P., 1990. Principles of drug action. In: The Basis of Pharmacology, 3rd ed. Churchill Livingstone, New York.
27. Prueksaritanont T., Gorham L.M., Hochmann J.H., Tran L.O., Vyas K.P. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug. Met. Disp. 24:1996;634-642.
28. Raeissi S.D., Hidalgo I.J., Segura-Aguilar J., Artursson P. Interplay between CYP3A4-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. Pharm. Res. 16:1999;625-632.
29. Rodrigues, A.D., 2002. Drug-Drug Interactions. Marcel Dekker, New York.
30. Romsicki Y., Sharom F.J. The membrane lipid environment modulates drug interactions with the P-glylcoprotein multidrug transporter. Biochemistry. 38:1999;6887-6896.
31. Sakaeda T., Okamura N., Nagata S., Yagami T., Hironouchi M., Okumura K., Yamashita F., Hashida M. Molecular and pharmacokinetic properties of 222 commercially available oral drugs in humans. Biol. Pharm. Bull. 24:2001;935-940.
32. Sandstrom R., Karlsson A., Knutson L., Lennernas H. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm. Res. 15:1998;856-862.
33. van der Sandt, I.C.J., 2001. P-Glycoprotein Mediates Drug Transport at the Blood Brain Barrier. Ph.D. Thesis. Universiteit Leiden.
34. Schinkel A.H. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Del. Rev. 36:1999;179-194.
35. Schmiedlin-Ren P., Thummel K.E., Fischer J.M., Paine M.F., Lown K.S., Watkins P.B. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1-alpha,25-dihydroxyvitamin D3. Mol. Pharmacol. 51:1997;741-754.
36. Stoner, C.L., Whittico, M.T., Fountain, S.T., Buchholz, L.M., Surendran, N., Chan, O.H., Stewart, B.H., Oh, D.M., 2000. High throughput P-glycoprotein interaction screening in Caco-2 cells for drug discovery compounds. In: Proceedings of the AAPS Annual conference, Indianapolis.
37. Taipalensuu J., Tornblom H., LIndberg G., Einarsson C., Sjoqvist F., Melhus H., Garberg P., Sjostrom B., Lundgren B., Artursson P. Correlation of gene expression of 10 drug efflux proteins of the ATP binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 299:2001;164-170.
38. Testa, B., van de Waterbeemd, H., Folkers, G., Guy, R., 2001. Pharmacokinetic optimization in drug research. In: Biological, Physico-Chemical, and Computational Strategies. Verlag Helvetica Chimica Acta, Zurich.
39. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84:1987;7735-7738.
40. Trouman, M.D., Thakker, D.R., 2001. Efflux ratio does not predict the role of P-glycoprotein in attenuating the intestinal absorption of its substrates. In: Proceedings of the AAPS Conference, Denver.
41. Versantvoort C.H.M., Onderwater R.C.A., Duizer E., Van de Sandt J.J.M., Gilde A.J., Groten J.P. Monolayers of IEC 18 cells as an in vitro model for screening the passive transcellular and paracellular transport across the intestinal barrier: comparison of active and passive transport with the human colon carcinoma Caco-2 cell line. Environ. Toxicol. Pharmacol. 11:2002;335-344.
42. Watanabe S., Sato T. Effect, of free acids on the binding of bovine and human serum albumin with steroid hormones. Biochim. Biophys. Acta. 1289:1996;385-396.
43. Williams, P.L., 1995. Gray's anatomy. In: The Anatomical Basis of Medicine and Surgery, 38th ed. Churchill Livingstone, New York.
44. Yamashita S., Furubayashi T., Kataoka M., Sakane T., Sezaki H., Tokuda H. Optimized conditions for prediction of intestinall drug permeability using Caco-2 cells. Eur. J. Pharm. Sci. 10:2000;195-204.
45. Yamazaki M., Neway W.E., Ohe T., Chen I.W., Rowe J.F., Hochman J.H., Chiba M., Lin J.H. In vitro substrate identification studies for P-glycoprotein mediated transport: species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther. 296:2001;723-735.
46. Yazdanian M., Glyn S.L., Wright J.L., Hawi A. Correlating, partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm. Res. 15:1998;1490-1494.
47. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth. Pharm. Res. 14:1997;763-766.